THORN RUN PARTNERS for THE BIOSIMILARS FORUM
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026.
Foreign entity interest: Merck KGaA, Novartis AG, Samsung Bioepis, Teva Pharmaceutical Industries Ltd., as identified on LD-1, are dues paying coalition members.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STUART CHAPMAN | — |
| ALEX DELPIZZO | — |
| THAYER SURETTE ROBERTS | — |
Medicare/Medicaid MMM
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act.
Foreign entity interest: Merck KGaA, Novartis AG, Samsung Bioepis, Teva Pharmaceutical Industries Ltd., as identified on LD-1, are dues paying coalition members.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STUART CHAPMAN | Chief of Staff, Representative Carolyn McCarthy; Chief of Staff, Representative Zack Space; Press Secretary, Senator Jay Rockefeller; Press Secretary, Representative Barbara Lee |
| ALEX DELPIZZO | Legislative Director/Legislative Asst, Rep. Ferguson; Staff Asst, House Transportation and Infrastructure Committee |
| THAYER SURETTE ROBERTS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.